Italia markets closed

Adicet Bio, Inc. (0HX7.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
14,62+0,48 (+3,39%)
Alla chiusura: 03:04PM BST
Schermo intero
Chiusura precedente14,14
Aperto14,60
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno14,60 - 14,81
Intervallo di 52 settimane14,60 - 14,81
Volume1.000
Media VolumeN/D
Capitalizzazione753,24M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-1,05
Prossima data utili10 ago 2022 - 15 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

    MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a pub

  • GlobeNewswire

    Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

    MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stoc

  • GlobeNewswire

    Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

    MENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold at the public offering price, less underwriting